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Abstract
With increasing body weight, macrophages accumulate in adipose tissue. There, activated
macrophages secrete numerous proinflammatory cytokines and chemokines, giving rise to
chronic inflammation and insulin resistance. Prostaglandin E2 suppresses macrophage
activation via EP4; however, the role of EP4 signaling in insulin resistance and type 2 diabe-
tes mellitus remains unknown. In this study, we treated db/dbmice with an EP4-selective
agonist, ONO-AE1-329, for 4 weeks to explore the role of EP4 signaling in obesity-related
inflammation in vivo. Administration of the EP4 agonist did not affect body weight gain or
food intake; however, in the EP4 agonist–treated group, glucose tolerance and insulin resis-
tance were significantly improved over that of the vehicle–treated group. Additionally,
administration of the EP4 agonist inhibited the accumulation of F4/80-positive macrophages
and the formation of crown-like structures in white adipose tissue, and the adipocytes were
significantly smaller. The treatment of the EP4 agonist increased the number of anti-inflam-
matory M2 macrophages, and in the stromal vascular fraction of white adipose tissue,
which includes macrophages, it markedly decreased the levels of proinflammatory cyto-
kines and chemokines. Further, EP4 activation increased the expression of adiponectin
and peroxidase proliferator–activated receptors in white adipose tissue. Next, we examined
in vitroM1/M2 polarization assay to investigate the impact of EP4 signaling on determining
the functional phenotypes of macrophages. Treatment with EP4 agonist enhanced M2
polarization in wild-type peritoneal macrophages, whereas EP4-deficient macrophages
were less susceptible to M2 polarization. Notably, antagonizing peroxidase proliferator–
activated receptor δ activity suppressed EP4 signaling-mediated shift toward M2 macro-
phage polarization. Thus, our results demonstrate that EP4 signaling plays a critical role in
obesity-related adipose tissue inflammation and insulin resistance by regulating macro-
phage recruitment and polarization. The activation of EP4 signaling holds promise for treat-
ing obesity and type 2 diabetes mellitus.
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Introduction
Obesity predisposes to several metabolic diseases such as insulin resistance, type 2 diabetes
mellitus (T2DM), and arteriosclerosis. Developing novel approaches for the prevention and
treatment of T2DM is a matter of great importance.
Excess calorie intake contributes to increased body weight, which is associated with larger adi-
pocytes, preadipocyte differentiation, and abnormal adipokine secretion [1]. Hypertrophic adipo-
cytes secrete monocyte chemotactic protein-1 (MCP-1), which promotes macrophage
infiltration into obese adipose tissue, thus inducing chronic, low-grade inflammation [2]. White
adipose tissue (WAT) is an important site for obesity-related chronic inflammation where adi-
pose tissue macrophages (ATMs) produce proinflammatory cytokines and chemokines, such as
tumor necrosis factor alpha (TNFα) andMCP-1 [3]. The activation of inflammatory signaling
can trigger whole-body insulin resistance by directly influencing insulin signaling [4–6].
There are two major phenotypes for macrophages, M1 (classically activated) and M2 (alter-
natively activated) [7]. M1 macrophages produce proinflammatory cytokines and are induced
by Th1 cell–derived interferon (IFN) γ and lipopolysaccharide (LPS). By contrast, M2 macro-
phages reduce inflammatory responses by producing anti-inflammatory factors, such as inter-
leukin (IL)-10 and transforming growth factor (TGF)-β [7], and mainly reside in lean adipose
tissue. When mice on a high-fat diet become obese, M1 macrophages accumulate in the adi-
pose tissue, resulting in a shift toward M1 polarity, suggesting that the M1/M2 polarization of
ATMs plays a key role in insulin resistance and T2DM [8].
Prostanoids, comprised of prostaglandin and thromboxane, are bioactive compounds syn-
thesized in response to various stimuli and are crucial for maintaining tissue homeostasis and
inflammation [9]. Prostaglandin E2 (PGE2) is one of the major prostanoids generated by the
metabolism of arachidonic acid by cyclooxygenase (COX) and PGE synthases [10]. It has four
G protein–coupled receptors: EP1 through EP4 [11]. PGE2 suppresses the production of proin-
flammatory cytokines and chemokines via EP4 in LPS–treated human and murine macro-
phages [12,13]. In fact, EP4 activation suppresses chronic inflammation in vivo by mitigating
macrophage activation during afflictions such as inflammatory bowel disease [14], ischemia-
reperfusion injury [15], atherosclerosis [16], allograft rejection after cardiac transplantation
[17], and abdominal aortic aneurysm [18]. In addition, EP4 signaling suppresses adipocyte dif-
ferentiation [19] and protects against the diabetogenic toxicity of streptozotocin in mice [20].
PGE2 mediates, at least partially, the biological effects of adiponectin (a crucial anti-inflamma-
tory and anti-atherosclerotic molecule including suppression of adipocyte differentiation [21]
and inhibition of ischemia-reperfusion injury [22].
These findings imply important roles for EP4 signaling in vivo in obesity-related chronic
inflammation and in the subsequent increase of insulin resistance. In this study, we pharmaco-
logically activated the EP4 receptor in db/dbmice to investigate the pathophysiological role of
EP4 signaling in obesity and T2DM.
Results
Treatment with an EP4-selective agonist significantly improves glucose
tolerance and insulin resistance in obese mice
To determine the role of EP4 signaling in obesity-related inflammation in vivo, we adminis-
tered the EP4-selective agonist ONO-AE1-329 or vehicle for 4 weeks to db/dbmice. The dosage
of the EP4 agonist was determined in accordance with previous reports using animal models of
inflammation [23,24]. ONO-AE1-329 treatment did not affect body weight gain (Fig 1A) or
food intake (Fig 1B). There was no significant difference in the plasma levels of total
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cholesterol, triglyceride, or hemoglobin A1C between the two groups (Table 1). Additionally,
liver weight and epididymal WAT did not differ significantly (Table 1). Despite similar meta-
bolic characteristics, treatment with the EP4 agonist markedly improved glucose tolerance (Fig
1C). In addition, the insulin tolerance test indicated that the EP4 agonist increased insulin sen-
sitivity (Fig 1D). Thus, EP4 activation ameliorated obesity-induced abnormal glucose tolerance
and insulin resistance.
Fig 1. Effects of EP4 activation on glucose tolerance and insulin resistance. Seven-week-old male db/
dbmice subcutaneously received either the EP4-selective agonist ONO-AE1-329 (0.3 mg/kg) or vehicle
twice a day for 4 weeks. (A) Change in body weight during the study period (n = 8 each). (B) Amount of food
intake (n = 8 each). (C) Results of glucose tolerance test: left, time-course of blood glucose levels; right, area
under curve (AUC) (n = 7–8 each). (D) Results of insulin tolerance test: left, time-course changes of blood
glucose levels; right, the inverse AUC (n = 13 each). All values are mean ± SEM. * p<0.05; ] p<0.01 vs.
vehicle.
doi:10.1371/journal.pone.0136304.g001
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EP4 signaling inhibits macrophage accumulation in crown-like structures
and inflammatory activation in obese adipose tissues
Accumulation of macrophages in adipose tissues elicits inflammation, which in turn, causes local
and systemic insulin resistance and T2DM [2,25]. Because several lines of evidence indicate that
EP4 signaling in macrophages has anti-inflammatory effects, we next investigated the impact of
EP4 activation on inflammatory burden in obese adipose tissue. Immunohistochemistry revealed
that the accumulation of F4/80-positive macrophages in crown-like structures (CLSs) within epi-
didymalWAT was markedly decreased in the EP4 agonist–treated group (Fig 2A and 2B).
Accordingly, the sizes of adipocytes in the EP4 agonist–treated group were significantly smaller
compared to that of the vehicle–treated group (Fig 2A and 2C). Though there was no significant
difference in the mRNA expression ofMcp-1 inWAT (S1A Fig), there was a trend towards
decreased secretion of MCP-1 protein in the EP4 agonist–treated mice (p = 0.054) (S1B Fig).
To investigate the effect of EP4 activation on ATM activation, we isolated stromal vascular
fraction (SVF) from epididymal WAT, which contains inflammatory cells including ATMs,
and then measured the mRNA levels of proinflammatory cytokines and chemokines. The EP4
agonist–treated group had decreased expression of a number of genes encoding proinflamma-
tory cytokines and chemokines such as Tnfα, Il-6,Mcp-1, and interferon gamma–induced pro-
tein 10 (Ip-10) (Fig 3). These results indicate that activation of EP4 signaling has potent anti-
inflammatory effects in ATMs.
EP4 signaling enhances the polarization of adipose tissue macrophages
toward the M2 phenotype
ATMs are comprised of two distinct subsets: the classically activated, proinflammatory M1
macrophages and the alternatively activated, anti-inflammatory M2 macrophages. The total
number of infiltrated macrophages and the M1/M2 balance of those macrophages determine
the features of chronic inflammatory diseases such as obesity and T2DM [8,26]. To evaluate
the polarization of ATMs, we performed quantitative PCR on total mRNA from epididymal
WAT. The expression of genes encoding the M2 markers mannose receptor (MR) and Cd163
was increased in the EP4 agonist–treated group, whereas the gene encoding the M1 marker
Cd11c was not significantly different between the two groups (Fig 4A). Peroxidase prolifera-
tor–activated receptor (PPAR) δ and PPARγ are key factors in polarizing macrophages to M2
status [26–29]. In our study, the expression of these genes in WAT was significantly increased
by consecutive administration of EP4 agonist (S2 Fig). Accordingly, immunofluorescence of
epididymal WAT demonstrated that F4/80+ CD163+ M2 macrophages, not F4/80+ CD11c+
M1 macrophages, were more abundant in the EP4 agonist–treated group (Fig 4B).
Table 1. Effects of EP4 agonist on metabolic parameters.
Measurement Vehicle ONO-AE1-329 p-value
T-Cho (mg/dl) 117.35 ± 21.71 115.51 ± 12.16 N.S.
TG (mg/dl) 141.27 ± 37.18 153.06 ± 33.89 N.S.
HbA1c (%) 6.28 ± 0.42 6.05 ± 0.22 N.S.
Liver (g) 2.49 ± 0.25 2.43 ± 0.17 N.S.
Epididymal WAT (g) 2.35 ± 0.09 2.30 ± 0.15 N.S.
Values are mean ± SEM (n = 3–8 each). T-Cho, total cholesterol; TG, triglyceride; HbA1c, Hemoglobin A1c; WAT, white adipose tissue.
doi:10.1371/journal.pone.0136304.t001
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Impact of EP4 signaling on the balance of adipokine secretion
Adipokines, including adiponectin, are produced and secreted from fat cells in adipose tissues
and regulate systemic insulin sensitivity [30]. The nuclear receptors PPARα and PPARγ regu-
late the expression of adiponectin [31,32]. Adiponectin, in turn, suppresses macrophage infil-
tration into adipose tissue and promotes alternative M2 macrophage activation [33,34]. In the
EP4 agonist–treated group, the expression levels of PPARα and PPARγ in WAT were signifi-
cantly increased, along with production of adiponectin (S2 Fig and Fig 5A). Consequently,
though not statistically significant (p = 0.079), the plasma levels of adiponectin exhibited a pos-
sible trend toward significance in the EP4 agonist–treated group (Fig 5B), suggesting that
polarization of ATMs toward the anti-inflammatory M2 phenotype balanced adipokine secre-
tion and improved insulin sensitivity in obese mice.
EP4 signaling promotes M2 macrophage polarization in isolated murine
macrophages
To investigate whether EP4 signaling directly influences macrophage polarization, we freshly
isolated peritoneal macrophages fromWTmice and performed in vitroM1/M2 polarization
Fig 2. Adipose tissue morphology. (A) Representative images of epididymal adipose tissue stained with
anti-F4/80 antibody (upper panel; the arrows indicate F4/80-positive cells) and H&E (lower panel) in db/db
mice administered EP4 agonist (right column) or vehicle (left column). Scale bars: 100 μm. (B) Percent of F4/
80+ CLS areas in mouse epididymal adipose tissue (n = 7 each). (C) Quantification of adipocyte size (n = 7
each). All values are mean ± SEM. ] p<0.01 vs. vehicle. CLS, crown-like structures.
doi:10.1371/journal.pone.0136304.g002
EP4 Signaling Ameliorates Adipose Tissue Inflammation
PLOS ONE | DOI:10.1371/journal.pone.0136304 August 26, 2015 5 / 16
assays as previously described [35]. The expression of marker genes for M1 and M2 macro-
phages was assayed by quantitative PCR. In WTmacrophages, LPS stimulation induced the
mRNA expression of M1 genes, such as Tnfα and Il-6, whereas adding the EP4 agonist to the
LPS mixture decreased the mRNA expression of those genes (Fig 6A). On the other hand, co-
stimulation with IL-4 and IL-13 enabled peritoneal macrophages to polarize to M2 status (Fig
6B). Notably, treatment with the EP4 agonist with IL-4 and IL-13 further increased the mRNA
expression of M2 genes, includingMR and Cd163 (Fig 6B).
To investigate the impact of EP4 deletion on macrophage polarization, we collected perito-
neal macrophages from EP4 knockout mice and estimated M1/M2 polarization. EP4 deficiency
resulted in increased susceptibility to M1 and less susceptibility to M2 macrophage polarization
(Fig 6C and 6D), suggesting that EP4 signaling may act directly on macrophage polarization.
These results indicate that the activation of EP4 signaling mitigates chronic inflammation in
adipose tissue by regulating ATM activation and polarization.
Next, we examined the downstream of EP4 signaling that enhanced M2 polarization. It is
well known that the activation of PPARs is one of the keys in polarizing macrophages to M2
status [26–29]. When we added GSK3787, PPARδ selective antagonist, prior to IL-4/IL-13 in
in vitroM1/M2 polarization assays, the EP4-dependent increase of Cd163 orMR gene expres-
sion markedly inhibited (Fig 6E). On the other hand, pretreatment of GW9662, PPARγ antago-
nist, suppressed the enhanced expression of Cd163 but notMR by EP4 agonist (Fig 6F). These
results suggest that PPARs, especially PPARδ, might coordinate EP4 signaling in macrophage
polarization toward an M2-like phenotype.
Discussion
Prostaglandin E2 (PGE2) has been shown to exert energy and metabolic homeostasis: for
instance, PGE2 regulates lipolysis and increases leptin release in primary culture of rodent and
Fig 3. Cytokine and chemokine gene expression in SVF. Relative expression of Tnfα, Il-6,Mcp-1, and Ip-
10mRNA in SVF isolated from db/dbmice administered EP4 agonist (black bar) or vehicle (white bar). All
values are mean ± SEM (n = 3 each). * p<0.05; ] p<0.01 vs. vehicle. SVF, stromal vascular fraction; Tnfα,
tumor necrosis factor α; Il-6, interleukin-6; Mcp-1, monocyte chemotactic protein-1; Ip-10, interferon gamma–
induced protein 10.
doi:10.1371/journal.pone.0136304.g003
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human adipose tissues [36–38], while EP3-deficient mice displayed increased feeding and body
weight despite elevated plasma leptin levels [39]. In addition, a previous report demonstrated
that intracerebroventricular administration of PGE2 or EP4 agonist decreased food intake in
Fig 4. Administration of EP4 agonist alters adipose tissue macrophage polarization. (A) Relative expression of marker genes for M1 (Cd11c) and M2
(MR, Cd163) macrophages in epididymal fat tissues from db/dbmice administered EP4 agonist (black bar) or vehicle (white bar). All values are mean ± SEM
(n = 4–5 each). ] p<0.01 vs. vehicle. (B) Epididymal adipose tissues of EP4 agonist–or vehicle–treated db/dbmice were double stained with anti-F4/80
(green), and anti-CD11c (red, upper panel) or anti-CD163 (red, lower panel) antibodies. Arrows indicate double-positive cells. Scale bar: 100 μm. MR,
Mannose Receptor.
doi:10.1371/journal.pone.0136304.g004
Fig 5. Impact of EP4 activation on adiponectin expression. Relative adiponectin mRNA levels in
epididymal fat tissue (A) and plasma adiponectin concentrations (B) were measured in EP4 agonist–(black
bar) or vehicle–treated (white bar) db/dbmice. All values are mean ± SEM (n = 6 each). ] p<0.01 vs. vehicle.
doi:10.1371/journal.pone.0136304.g005
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fasted mice [40]. In this study, however, administration of EP4 selective agonist did not affect
body weight gain, food intake or blood lipid profile. It may be partially because that in our
study, we used leptin receptor-deficient db/dbmice fed with normal chow ad libitum, and
administered EP4 agonist peripherally. Besides, in WAT, other EP receptors including EP3
express and activate intracellular signal transduction pathways differing from EP4.
EP4 activation is pivotally involved in ameliorating chronic inflammatory diseases [14–
16,41]. Macrophages, known to have abundant EP4 expression [12], accumulate in hypertro-
phied adipose tissues and play crucial roles in the pathogenesis of insulin resistance and T2DM
by promoting inflammation. Therefore, we examined the impact of EP4 signaling on obesity-
related adipose tissue inflammation in vivo using an animal model of obesity and T2DM.
Obesity is generally caused by the combination of excess calorie intake, insufficient physical
activity, and genetic predisposition. Obese adipose tissue is characterized by hypertrophied
Fig 6. EP4 signaling is important in macrophage polarization. In vitroM1/M2 polarization assays were performed using peritoneal macrophages freshly
isolated from 12 to 15-week-old male WT (white bar) or EP4-deficient mice (black bar). To determine M1 or M2 polarization, cells were incubated with 1 μg/ml
of LPS (A, C), or with 20 ng/ml of IL-4 and IL-13 (B, D), as well as with 1 μM of EP4 agonist or vehicle. Eight hours later, marker gene expression for M1 (Tnfα
and Il-6) (A, C) or M2 (MR andCd163) (B, D) polarity was measured. To clarify the role of PPARs in EP4-dependent M2 polarization, peritoneal macrophages
were pretreated with GSK3787 (PPARδ antagonist) (E), GW9662 (PPARγ antagonist) (F) or vehicle prior to the administration of IL-4/IL-13 and the EP4
agonist. Results are expressed as the fold induction of M2 genes compared with unantagonized, vehicle-treated cells. All values are mean ± SEM (n = 6
each). * p<0.05; ] p<0.01. LPS, lipopolysaccharide.
doi:10.1371/journal.pone.0136304.g006
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adipocytes, increased production of proinflammatory cytokines and chemokines, and infiltra-
tion by immune cells, including macrophages [42]. Though there was no significant difference
in the weight of epididymal adipose tissue in our study, the adipocytes were less hypertrophied
in the EP4 agonist–treated group. Hypertrophied adipocytes secrete MCP-1, leading to the
recruitment of circulating monocytes and subsequent infiltration by macrophages into adipose
tissues. Infiltrated ATMs, in turn, secrete MCP-1 and other proinflammatory cytokines and
chemokines; consequently a number of ATMs accumulate in adipose tissues, causing chronic
inflammation in WAT [2,8,25]. PGE2-EP4 signaling suppresses MCP-1 expression in a variety
of inflammatory settings [43,44]. Our data demonstrated that consecutive administration of
EP4 receptor–agonist into obese mice significantly decreased MCP-1 production in SVF, a
fraction containing macrophages but not adipocytes, suggesting that EP4 signaling mainly
affects ATMs and inhibits the deleterious consequences of local chemokine production and
macrophage infiltration.
Obesity causes a shift in macrophage polarity from the anti-inflammatory M2 to the pro-
inflammatory M1 state, facilitating insulin resistance [8]. Using mice with mutations in key
proteins of the inflammatory process, it has been demonstrated that an increase in M2 ATMs
ameliorates obesity-related impaired glucose metabolism. In one example, mice lacking Trib-
bles homolog 1 (Trib1, which encodes an adaptor protein involved in proteasome-mediated
protein degradation) in hematopoietic cells develop glucose intolerance and insulin resistance
on a high-fat diet. They have a severely reduced number of M2 ATMs, but no change in M1
ATMs [45]. Hematopoietic deletion of COX-1, a major PGE2-producing enzyme, was also
associated with metabolic disorders and decreased counts of M2 ATMs in diet-induced obese
mice, with M1 counts remaining the same [46]. How M2 ATMs contribute to the amelioration
of glucose tolerance and insulin resistance is not fully understood; however, a number of previ-
ous reports indicated that M2 macrophages reside in adipose tissues have crucial roles in main-
taining normal glucose homeostasis [3,47,48]. Polarized M2 ATMs secrete anti-inflammatory
cytokines such as IL-10, improving insulin-stimulated glucose uptake in TNFα–treated 3T3-L1
adipocytes [8]. In addition to secreting cytokine or regulating adipokine production, some of
M2 ATMs can store large amount of iron: loss of these alternatively activated macrophages
may cause abnormal accumulation of iron in adipocytes and enhance iron-induced lipid perox-
idation and oxidative stress, which consequently deteriorate adipocyte insulin sensitivity [49].
Besides, M2 ATMs are capable of producing catecholamines such as norepinephrine, activating
β3 adrenergic receptor on adipocytes: β3 adrenergic receptor signaling in WAT is pivotally
involved in metabolic homeostasis through regulating lipolysis and mitochondrial functions
[50,51].
Accordingly, we observed that the activation of EP4 signaling increased the number of M2
macrophages and led to a phonotypic switch toward M2 status in obese adipose tissue. Notably,
in our study, EP4 signaling pivotally participated in M1/M2 differentiation in vitro, and in EP4
agonist–treated mice, the gene expression of PPARδ and PPARγ in WAT were significantly ele-
vated. PPARδ is induced in response to adipocyte-derived Th2 cytokines, such as IL-4 and IL-
13, and facilitates adipocyte differentiation, as well as the recruitment of M2 macrophages into
adipose tissue and the liver [27,28]. PPARγ is necessary for the alternative activation of ATMs
[26,29]. Thus, our data suggest that EP4 activation regulates macrophage accumulation in
obese adipose tissue, as well as differentiation and polarization toward M2 phenotypes, result-
ing in the suppression of adipose tissue inflammation.
Adipose tissues secrete various adipokines, and the plasma adipokine levels can be an indi-
cator of systemic inflammation and insulin resistance. Adiponectin is one of the major adipo-
kines, exhibiting anti-diabetic, anti-atherosclerotic, and anti-inflammatory properties [52]. The
activation of PGE2-EP4 signaling is crucial for the protective function of adiponectin [22]. In
EP4 Signaling Ameliorates Adipose Tissue Inflammation
PLOS ONE | DOI:10.1371/journal.pone.0136304 August 26, 2015 9 / 16
addition, adiponectin promotes the alternative activation of macrophages and polarization
toward the anti-inflammatory M2 phenotype [34,53]. Our study indicates that consecutive EP4
activation induces local adiponectin production in WAT, which in turn, might contribute to
the phenotypic shift of ATMs into M2 status and suppression of adipose tissue inflammation.
In contrast to enhanced adiponectin mRNA levels in WAT, we observed no statistically signifi-
cant change in the plasma levels of total adiponectin in EP4 agonist–treated group; yet some
previous works demonstrated that insulin sensitivity does not always correlate with the plasma
total adiponectin levels, because adiponectin circulates in the blood in multimeric forms with
different metabolic activities [54,55].
Defining the precise mechanisms by which EP4 activation enhances M2 polarization is
beyond the scope of the current study; however, as discussed above, successive treatment of
obese mice with EP4-selective agonist enhances PPARγ, PPARδ, and adiponectin expression,
which may explain the polarity shift of accumulated macrophages, at least partially. EP4 is cou-
pled to Gs, which stimulates adenylate cyclase, and thus, increases intracellular cAMP levels,
consequently activating protein kinase A and cAMP response element binding protein (CREB)
[56]. In differentiated 3T3-L1 adipocytes, adiponectin expression is mediated through cAMP–
CREB–PPARγ pathways [57], but it remains controversial whether PGE2 or EP4 signaling
directly acts on the expression of these genes via a cAMP-dependent pathway. Unlike other EP
receptors coupled with Gs, EP4 has a long cytoplasmic tail, where the receptor interacts with a
novel protein designated EP4 receptor–associated protein (EPRAP) [12]. Because EPRAP
exerts an anti-inflammatory effect in LPS-stimulated macrophages in vitro [12,13], EPRAP
may also contribute to the suppression of obesity-related inflammation.
In this study, we focused on the impact of EP4 signaling in adipose tissues on macrophage
activation and polarization. PGE2 regulates the profibrotic and proinflammatory activation of
pancreatic stellate cells via EP4 and protects β-cells from apoptosis [58,59]. Other than adipose
tissues, macrophages also infiltrate into the liver and the skeletal muscle in obese subjects, and
the polarity appears to be shifted towards M1 status, which has a strong association with dys-
function of these organs and with insulin resistance [27,28,60]. Clarifying the roles of EP4 sig-
naling in macrophage activation and phenotypic switching within these organs could be
important for understanding the novel pathophysiological mechanisms of insulin resistance
and T2DM.
In summary, administration of an EP4-selective agonist improved insulin sensitivity and
glucose tolerance in obese mice. Treatment with EP4 agonist inhibited the accumulation of
macrophages and decreased CLS formation, consequently attenuating the expression of proin-
flammatory cytokines and chemokines, and enhancing adiponectin production in white adi-
pose tissue. EP4 activation promoted ATM polarization toward the M2 phenotype in obese
mice; accordingly, our in vitro experiments verified that EP4 signaling played a crucial role in
the differentiation and polarization of murine peritoneal macrophages. Further investigation
to clarify the detailed molecular mechanisms underlying the effects of EP4 signaling on macro-
phage differentiation and polarization in other insulin-target organs will provide new insights




All animal care and experiments were conducted following the guidelines for the Japan’s Act
onWelfare and Management of Animals (Act No. 105 of October 1, 1973). These studies were
approved by the Institutional Animal Care and Use Committees (IACUC)/ethics committee of
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Kyoto University (Permit Number: MedKyo15183). All sections of this report are based on the
ARRIVE Guidelines for reporting animal research [61]. A completed ARRIVAL guidelines
checklist is included in S1 Checklist. All surgery was performed when mice were anesthetized
by 40 mg/kg of pentobarbital sodium (Kyoritsu Seiyaku, Tokyo, Japan); blood and tissue collec-
tion were performed as terminal procedures under anesthesia as described above, and all efforts
were made to minimize suffering.
Animals
Five-week-old male db/dbmice were obtained from Oriental BioService (Kyoto, Japan). Homo-
zygotic EP4-deficient mice and WTmice with the same genetic background were obtained by
crossing mice heterozygous for the PTGER4mutation and were verified as previously described
[62]. We used 26 db/dbmice housed in groups of 2. Other varieties of mice had 6 mice per
group and were housed in groups of 6. Mice were maintained in a specific pathogen-free facility
(12 h light/dark cycles) and were fed normal chow ad libitum unless otherwise indicated.
Treatment of db/db mice with EP4 receptor–selective agonist
ONO-AE1-329 (Ono Pharmaceutical, Osaka, Japan), an EP4-selective agonist [14,63], was sus-
pended in vehicle (0.3% ethanol and 0.1% Tween 80 in PBS), and 0.3 mg/kg of the reagent or
vehicle was administrated subcutaneously to 7-week-old db/dbmice twice a day for 4 weeks.
We allocated animals into 2 groups as the vehicle–treated group and the ONO-AE1-329–
treated group with 13 mice based on body weight (vehicle: 38.93 ± 0.62, ONO-AE1-329:
39.78 ± 0.52; mean ± SE, no significant difference) at the start of the experiment in order to
minimize the effect of subjective bias.
Glucose and insulin tolerance test
After an overnight fast, we administered 1.5 g/kg of D(+)-glucose (Wako Pure Chemical Indus-
tries, Osaka, Japan) and 0.75 U/kg of Humulin R (Eli Lilly Japan, Kobe, Japan) intraperitoneally
to perform the glucose tolerance test (ipGTT) and the insulin tolerance test (ITT), respectively.
Plasma variables
Plasma levels of blood glucose (BG), total cholesterol (T-Cho), triglyceride (TG), hemoglobin
A1c (HbA1c), and adiponectin were measured using the Glucose CII Test Wako (Wako), the
Total Cholesterol E-Test Wako (Wako), the Triglyceride E-Test Wako (Wako), the Glycohe-
moglobin A1c kit (Sanwa Kagaku Kenkyusho, Nagoya, Japan), and the Adiponectin ELISA kit
(Otsuka Pharmaceutical, Tokyo, Japan), respectively.
Histology
Epididymal adipose tissue was harvested and fixed overnight with 4% paraformaldehyde
(Wako), embedded in paraffin, and sectioned. For H&E staining, we stained the rehydrated
sections using Mayer’s hematoxylin solution (Wako). For immunohistochemistry, the rehy-
drated sections were blocked with Protein Block Serum-Free (Dako, Glostrup, Denmark) and
the macrophages were stained using rat monoclonal anti-F4/80 antibody (Abcam, Cambridge,
MA, USA; clone CI:A3-1, 1:100; AB_1140040) and visualized by coloring with diaminobenzi-
dine (DAB; Vector Laboratories, Burlingame, CA, USA). For immunofluorescence staining,
blocked sections were incubated with a combination of rat anti-F4/80 antibody (Abcam; clone
CI:A3-1, 1:100; AB_1140040) and either rabbit polyclonal anti-CD11c antibody (Santa Cruz
Biotechnology, Dallas, TX, USA; clone M-50, 1:100; AB_2129774) or rabbit polyclonal anti-
EP4 Signaling Ameliorates Adipose Tissue Inflammation
PLOS ONE | DOI:10.1371/journal.pone.0136304 August 26, 2015 11 / 16
CD163 antibody (Santa Cruz Biotechnology; clone M-96, 1:100; AB_2074556). After washing,
the sections were incubated with Alexa Fluor 488–conjugated donkey anti-rat antibody (Invi-
trogen, Carlsbad, CA, USA) or Alexa Fluor 594–conjugated donkey anti-rabbit antibody (Invi-
trogen). Non-immune rat IgG (Vector Laboratories) and rabbit IgG (Santa Cruz
Biotechnology) served as negative controls for each experiment.
Quantitative PCR
Total RNA was extracted from adipose tissue, stromal vascular fraction (SVF), and peritoneal
macrophages using the RNeasy Lipid Tissue Mini kit (Qiagen, Valencia, CA, USA), RNeasy
Micro kit (Qiagen), and RNeasy Mini kit (Qiagen), respectively. RNA was reverse-transcribed
by High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems, Forster City, CA,
USA). Samples were processed on the 7300 Real-Time PCR System (Applied Biosystems)
using the Power SYBR Green PCR Master Mix (Applied Biosystems). All experiments were
performed in duplicate, and results were normalized to β-actin expression level. The sequences
of the sense and antisense primers used for amplification are as follows; β-actin: 5'-CCTGAGC
GCAAGTACTCTGTGT-3’, 5'-GCTGATCCACATCTGCTGGAA-3’; Tnfα: 5'-CATCTTCTC
AAAATTCGAGTGACAA-3’, 5'-TGGGAGTAGACAAGGTACAACCC-3’; Il-6: 5'-TAGTCC
TTCCTACCCCAATTTCC-3’, 5'-TTGGTCCTTAGCCACTCCTTC-3’;Mcp-1: 5'-GC
TGGAGCATCCACGTGTT-3’, 5'-ATCTTGCTGGTGAATGTGTAGCA-3’; IP-10: 5’-GCC
GTCATTTTCTGCCTCAT-3’, 5’-GCTTCCCTATGGCCCTCATT-3’; Cd11c: 5'-CTGGAT
AGCCTTTCTTCTGCTG-3’, 5'-GCACACTGTGTCCGAACTC-3’;MR: 5'-GCTGAAT
CCCAGAAATTCCGC-3’, 5'-ATCACAGGCATACAGGGTGAC-3’; Cd163: 5'-GGGTCATT
CAGAGGCACACTG-3’, 5'-CTGGCTGTCCTGTCAAGGCT-3’; Adiponectin: 5'- GAT
GGCAGAGATGGCACTCC-3’, 5'-CTTGCCAGTGCTGCCGTCAT-3’; PPARδ: 5'-AGAT
GGTGGCAGAGCTATGACC-3’, 5'-TCTCCTCCTGTGGCTGTTCC-3’; PPARγ: 5'-CT
CCAAGAATACCAAAGTGCGA-3’, 5'-GCCTGATGCTTTATCCCCACA-3’; PPARα: 5'- AT
GCCAGTACTGCCGTTTTC-3’, 5'-CCGAATCTTTCAGGTCGTGT-3’.
Isolation of stromal vascular fraction (SVF)
Epididymal adipose tissues were minced and digested in 0.2% collagenase (Wako) in PBS for
2 h at 37°C. The digested tissues were passed through a 100 μm nylon mesh filter (BD Biosci-
ences, San Jose, CA, USA) to remove the floating adipocytes, and the filtrates were spun for
5 min at 1,200 rpm. The pellet was incubated with Lysing Buffer (BD Biosciences) for 2 min to
remove the red blood cells.
In vitro M1/M2 polarization assay
Peritoneal macrophages were extracted from the peritoneal lavage of 12 to 15-week-old male
EP4-deficient mice or WT mice with the same genetic background. The in vitroM1/M2 polari-
zation assay was performed as previously described [35]. Briefly, together with 1 μM of
ONO-AE1-329 or vehicle, peritoneal macrophages were treated with 1 μg/ml of LPS (Escheri-
chia coli O55: B5, Calbiochem, La Jolla, CA, USA) or 20 ng/ml of IL-4 (R&D Systems, Minne-
apolis, MN, USA) and IL-13 (R&D Systems) for 8 h. Meanwhile, to explore the roles of PPARs
in EP4-dependent M2 polarization, 0.1 μM of GSK3787 (Tocris Bioscience, Bristol, UK), selec-
tive antagonist for PPARδ, or 1 μM of GW9662 (Cayman Chemical, Ann Arbor, MI, USA),
selective antagonist for PPARγ, was added into the medium 2h before IL-4/IL-13 and the EP4
agonist treatment.
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Cytometric bead assay
Epididymal WAT was homogenized in RIPA buffer (Wako) with Protease inhibitor cocktail
(Roche Diagnostics, Indianapolis, IN, USA). MCP-1 concentration in the supernatants of epi-
didymal WAT homogenates was measured using the BD CBA assay (BD Biosciences).
Statistical analysis
Results are presented as the mean ± SEM. All data were analyzed with Kaleida Graph software
(version4.1J; Synergy Software, Reading, PA, USA). Differences between two value sets were
determined using the unpaired, two-tailed Student’s t-test. A one-way ANOVA followed by
Turkey-Kramer analysis was used for testing the differences among three or more groups. Sig-
nificance was defined as a p-value less than 0.05.
Supporting Information
S1 Checklist. Completed ARRIVE Guidelines Checklist for reporting animal data in this
manuscript.
(PDF)
S1 Fig. Impact of EP4 activation on MCP-1 production in adipose tissue. The relative
mRNA levels (A) and the protein concentrations (B) of MCP-1 in epididymal adipose tissue
were measured in db/dbmice administered EP4 agonist (black bar) or vehicle (white bar). All
values are mean ± SEM (A: n = 6 each, B: n = 6–8 each).
(TIF)
S2 Fig. EP4 activation enhances the gene expression levels of PPARs in adipose tissue. Rela-
tive expression of PPARδ, PPARγ, and PPARαmRNA in epididymal adipose tissue from db/db
mice administered EP4 agonist (black bar) or vehicle (white bar). All values are mean ± SEM
(n = 4–5 each). ] p<0.01 vs. vehicle. PPAR, peroxidase proliferator–activated receptor.
(TIF)
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